Analysis of a New Biomarker for Prostate Cancer Diagnosis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01819740

Acronym

HEM

Enrollment

Registered

2013-03-28

Start date

2013-04-30

Completion date

Unknown

Last updated

2013-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Suspected Prostate Cancer

Brief summary

The aim of our study is to determine if the levels of the HEM substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.

Interventions

OTHERdetermine the levels of the HEM substance in seminal plasma

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

45 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Clinical or laboratory suspected of prostate cancer

Exclusion criteria

* Inability to ejaculate

Design outcomes

Primary

Measure	Time frame
substance HEM concentration in seminal plasma (mEq/L measured by spectro-photometry	1 hour

Countries

Spain

Contacts

Primary ContactMiriam Barrio-Muñoz

mbarrio6@gmail.com34 93 723 10 10

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026